FDA granted accelerated approval for TRUTAKNA, the first BAFF and APRIL inhibitor, to reduce proteinuria in adults with primary IgA nephropathy. Approval is based on significant proteinuria reduction in the ORIGIN 3 trial, with ongoing studies to confirm long-term benefits.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.